Background. Protection against dengue requires immunity against all 4 serotypes of dengue virus (DENV). Experimental challenge may be useful in evaluating vaccine-induced immunity.
Dengue is an arboviral disease caused by 4 serotypes of dengue virus (DENV). It is the leading vectorborne disease in humans, with >50 million infections annually worldwide, and has the potential to be reestablished in parts of the United States [1] . Existing dengue prevention and control strategies have failed to prevent the expansion of this disease [2] . Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are the severe forms of the disease, occurring usually from secondary infection by a heterologous serotype, and account for the majority of fatalities [3] . The pathogenesis of DHF and DSS has been postulated to be mediated by antibody-dependent enhancement [4, 5] . An effective dengue vaccine is urgently needed [6, 7] . A tetravalent vaccine should simultaneously immunize against all 4 DENV serotypes.
Neutralizing antibodies (NAb) developed after infection confer both long-lasting protection against reinfection by the homologous serotype and transient cross-protection against heterologous serotypes [8] . Although the protective levels of serotype-specific NAb have not been established, the NAb titer measured by the 50% plaque reduction neutralization test (PRNT 50 ) has been generally accepted as the immune response end point for dengue vaccine trials [9] . Because of the cross-reactivity of NAb among the serotypes and the phenomenon of original antigenic sin, it is difficult to infer the immune status of any particular individual in whom infections with multiple DENV serotypes have occurred [10] . Similarly, in the setting of live attenuated tetravalent dengue vaccine (TDV), it is difficult to infer vaccine-induced protection on the basis of the presence of NAb against multiple serotypes because of the presence of cross-reactive, nonprotective NAb. The cross-reactive, nonprotective NAb may contribute to antibody-dependent disease enhancement [4, 5] . This has been a major theoretic concern for dengue vaccine developers. A suboptimally immunogenic vaccine not only might fail to protect but also might pose an increased risk of DHF following subsequent natural infection [11] . Currently, the tetravalent live attenuated vaccine approach is in late-phase development [6, 7] . We have evaluated several TDV formulations in clinical trials [12] [13] [14] [15] [16] [17] [18] [19] [20] . Here, we evaluate TDVinduced immunity in selected previously vaccinated subjects by experimentally challenging them with underattenuated monovalent DENV-1 or DENV-3 [21] .
MATERIALS AND METHODS

Study Design
This was a descriptive, phase II, controlled, open-label experimental challenge study. The primary study objectives were (1) to evaluate the safety of giving either underattenuated DENV-1, DENV-3, or attenuated DENV-3 to subjects previously vaccinated with TDV, (2) to determine whether DENV-1 and DENV-3 NAb elicited by TDV protect against clinical disease from homologous-serotype challenge virus, and (3) to determine the clinical safety and immunogenicity of DENV-3 revaccination in TDV recipients who did not develop DENV-3 NAb from previous TDV vaccination. Secondary objectives were to study cell-mediated immunity in study subjects, the results of which are described elsewhere [22] . Three study arms-challenge, revaccination, and control-were used. Subjects in the challenge and revaccination arms were vaccinated with 2 doses of TDV 12-42 months before this study. Subjects in the control arm were flavivirus naive.
Enrollment Criteria
All subjects were healthy adults 18-45 years of age. Subjects in the challenge and revaccination arms were recruited from subjects who previously participated in TDV clinical trials [15, 16, 18] . The challenge subjects had to have had a DENV-1 or DENV-3 NAb response following vaccination to be considered for homologous DENV-1 or DENV-3 challenge, to reduce the potential risk of DHF following challenge. For inclusion in the study, control subjects had to be flavivirus seronegative. All subjects provided written informed consent and had to score >75% on a written knowledge examination about the study, to demonstrate their comprehension of the risks of the study. The study was approved by institutional review boards. The study was conducted in accordance with current good clinical practices under Title 21 of the US Code of Federal Regulations, Parts 50, 56, and 312. The study was completed in 2002, prior to the implementation of the National Clinical Trials Registry.
Study Procedures
All baseline evaluations were done ≤28 days before challenge. Subjects were inoculated on day 0 and monitored for 30 minutes. A self-reported symptom and temperature diary was kept for 3 weeks. Symptoms were graded on a scale of 0-3, with 0 defined as none, 1 defined as mild (the symptom did not affect normal activity, and no medication was required), 2 defined as moderate (the symptom required medication or a change in activity level), and 3 defined as severe (the symptom required bed rest or was unrelieved by medication). A reactogenicity index (RI), a quantitative measurement of the severity of clinical symptoms, was calculated for each subject on the basis of 9 solicited dengue symptom grades and durations [16] . From days 4 to 17, when viremia and clinical illness were most likely to occur, all subjects were housed in quarters and monitored by a study physician at least twice daily, with vital signs recorded every 8 hours. Blood samples were obtained on days 0, 4-17 (daily), 24, 30, and 60 for laboratory tests. Subjects were hospitalized as a precaution if they developed an oral temperature of >38.0°C, thrombocytopenia (ie, a platelet count of <100 000 platelets/µL), hemoconcentration (ie, hematocrit increase of >15% from baseline), or any significant clinical illness. Follow-up after day 17 included telephone contact on day 21 and clinic visits on days 24, 30, and 60. A tourniquet test was done on all subjects at baseline and daily on subjects who developed fever, until 2 days after defervescence.
Laboratory Studies
Inclusion criteria included normal baseline results of the following laboratory tests: serologic analyses for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus; complete blood count (CBC) with differential; and determination of aspartate transaminase (AST) level, the alanine transaminase (ALT) level, international normalized ratio (INR), prothrombin time/partial thromboplastin time (PT/PTT), blood urea nitrogen level, blood glucose level, and creatinine level. Chest radiography and abdominal ultrasonography were performed at baseline and during fever. Abdominal ultrasonography was repeated if the subject became febrile, to evaluate for gallbladder wall thickening and ascites. Before challenge, all control subjects were seronegative to DENV-1, -2, -3, and -4, West Nile virus, yellow fever virus, St. Louis encephalitis virus, and Japanese encephalitis virus by hemagglutination inhibition assays and were seronegative to DENV-1, -2, -3, and -4 and yellow fever virus by PRNT 50 . Pregnancy was excluded by a negative serum β human chorionic gonadotropin (β-HCG) test result within 48 hours of inoculation and a negative urine β-HCG test result on day 0. On days 4-17, CBC with differential was measured daily, and PT/PTT, AST level, ALT level were measured every 2 days. A platelet count of <20 000 platelets/µL and an ALT level of >1000 IU/L were considered to be serious adverse events.
Challenge and Vaccine Viruses
The DENV-1 and DENV-3 strains were chosen because these 2 challenge strains consistently caused fever in previous clinical trials. The challenge DENV-1 and DENV-3 were derived from clinical DENV isolates, using a seed lot system under current Good Manufacturing Practices, which involves passages in cell cultures, as described by Eckels et al [12, 19, 23] . DENV-1 45AZ5 PDK-0 (DENV-1-Ch) and DENV-3 CH53489 cl 24/28 PDK-0 (DENV-3-Ch) had failed evaluation as vaccine candidates because of their reactogenicity [19, 20] . When given at 10 4 plaque-forming units (PFU) subcutaneously, both strains previously consistently elicited dengue fever in 4 and 5 adult subjects, respectively [20, 23, 24] . Both challenge viruses were parental in lineage to the respective vaccine strains in the TDV. The DENV-3 component of the TDV, DENV-3 CH53489 cl 24/28 PDK-20 (DENV-3 PDK20), was used in the revaccination arm. All test articles were given as 0.5 mL subcutaneous injections in the deltoid region. Residuals in the multidose vial were verified for potency by a plaque assay on Vero cells. The doses of DENV-1-Ch, DENV-3-Ch, and DENV-3 PDK20 were 10 3 PF, 10 5 PFU, and 10 4 PFU, respectively.
Viremia
Blood specimens collected on days 0 and 4-17 were tested for viremia by delayed plaque assay [25] and by serotype-specific quantitative real-time reverse transcription polymerase chain reaction (RT-PCR), using ABI Prism 7900HT as previously described [26] . Primers and probes were based on the 5′ untranslated region of DENV. The limit of quantitation for the assay was determined to be 5.1 × 10 1 and 1.0 × 10 1 genome copies/mL for DENV-1 and DENV-3, respectively [26] .
Immunogenicity
NAb titers were measured on days 0, 30, and 60, using PRNT 50 involving a 6-well format with Vero cells [27] . All samples were tested in triplicate. A positive test cutoff was defined as a 50% reduction in plaques at a dilution of 1:10.
Data Analysis
This was a descriptive study with a small sample size and did not formally test any hypothesis. Data are tabulated individually for each subject.
RESULTS
Subject Disposition
There were 135 eligible subjects from 3 previously completed TDV phase I and II clinical trials. Thirty-nine of 135 eligible subjects were available. Of these, 12 subjects completed screening, and 5 (subjects TD1_1-5) were selected for DENV-1 challenge, 5 (subjects TD3_1-5) were selected for DENV-3 challenge, and 2 (subjects TV3_1 and TV3_2) were selected for DENV-3 monovalent revaccination. The assignment of the serotype challenge was based on the highest postvaccination DENV-1 and DENV-3 PRNT 50 titers. Two subjects were selected for DENV-3 revaccination because of their lack of postvaccination DENV-3 antibody. The subjects were blinded to the serotype of challenge or revaccination. The 4 control group subjects (subjects CD1_1, CD1_2, CD3_1, and CD3_2) were selected from 19 screened individuals. The demographic characteristics of the subjects are shown in Table 1 . All 16 subjects completed the study per protocol.
Clinical Safety
Local reactions from the injections were minimal. The only subject with an observable local sign was a DENV-3-Ch control subject, in whom a 3.5 × 1.0-cm area of erythema emerged at the injection site by day 4 and resolved by day 5. No subjects developed DHF or DSS, as defined by World Health Organization criteria [28] . Specifically, no subjects developed hemoconcentration, positive tourniquet sign, ascites, gallbladder wall thickening, bleeding, hypotension, or laboratory-determined serious adverse events.
DENV-1 Challenge
Of the 5 TDV recipients given DENV-1-Ch, none developed dengue illness (Table 2) . Only 1 vaccinee, subject TD1_5, developed fever and headache (duration, 1 day), which were due to a tooth abscess. Both DENV-1-Ch controls, subjects CD1_1 and CD1_2, developed fever of 39.3°C (grade 3) and 38.3°C (grade 1) orally, respectively, and had dengue symptoms that lasted 2-6 days. Subject CD1_2 had the most severe symptoms, with an RI of 30. No vaccinees developed generalized rash. The incubation periods in the control subjects were long, at 21 days for subject CD1_1 and 17 days for subject CD1_2. Subject CD1_1 developed the typical maculopapular generalized rash. No subjects who received DENV-1-Ch developed neutropenia or thrombocytopenia. Subject CD1_1 was the only DENV-1-Ch subject who developed elevated AST and ALT levels, in whom peaks of 41 IU/mL and 56 IU/mL, respectively, were observed.
DENV-3 Challenge
Three of 5 vaccinees, subjects TD3_1, TD3_2, and TD3_4, developed dengue-like illness ( Table 2) . The other 2, subjects TD3_3 and TD3_5, remained well. Subjects TD3_1 and TD3_4 developed grade 3 fever and symptoms. The clinical illness in TDV recipients was no worse than that in controls. The RIs for the symptomatic vaccinees were 17 (for subject TD3_1), 17 (for subject TD3_2), and 20 (for subject TD3_4), and the RIs for the control subjects were 21 (for subject CD3_1) and 63 (for subject CD3_2). Subjects TD3_2 and TD3_4 developed the typical maculopapular generalized rash of dengue, which lasted 4-5 days. Both control subjects developed dengue-like illness associated with grade 2 fever and generalized rash. Onset of symptoms with DENV-3-Ch occurred on 2-5 days after inoculation. TDV recipient TD3_1-3 and control subject CD3_1 developed transient neutropenia characteristic of dengue. Subject CD3_1 developed thrombocytopenia. Except for subject TD3_5, all subjects who were challenged with DENV-3-Ch developed elevated ALT levels (Table 3) . Subjects TD3_1, TD3_2, and CD3_1 had markedly elevated AST and ALT levels. The ALT level peaked at 977 IU/L (on day 9) and 428 IU/L (on day 13) in 2 of these subjects. The elevations lasted from days 5 to 30 and days 5 to 24 in subjects TD3_1 and TD3_2, respectively. Subject CD3_1, a control, had elevated AST and ALT levels on days 9-24, which peaked at 367 IU/L (for AST) and 349 IU/L (for ALT) on days 13 and 15, respectively. The AST and ALT levels returned to normal by day 30 in all 3 subjects. The INRs were normal for all DENV-3-Ch subjects throughout the study. No subjects had any evidence for DHF, such as abnormal hemoconcentration, pleural effusion, ascites, hepatomegaly, or gallbladder wall thickening.
DENV-3 Revaccination
The 2 TDV recipients who were revaccinated with the attenuated DENV-3 component from the original TDV they received did not develop any clinical symptoms or any clinically significant abnormal laboratory findings.
Viremia and NAb
DENV-1 Challenge
Of the 5 TDV recipients, all but subject TD1_2 were viremic with DENV-1 from their previous vaccination with TDV (data not shown). Four of the 5 TDV recipients had NAb to DENV-1 at the time of challenge, with reciprocal PRNT 50 titers of 415, 235, 451, and 198. Subject TD1_3 did not have measurable DENV-1 NAb at the time of and after challenge, yet he remained well after challenge. Only 1 TDV recipient, subject TD1_4, developed viremia, which was detected only on day 7, by delayed plaque assay but not RT-PCR, and she did not develop dengue (Table 4) . None of the TDV recipients challenged with DENV-1-Ch developed a rise in PRNT 50 titer after challenge, suggesting a lack of significant viral replication. As expected, both controls, subjects CD1_1 and CD1_2, seroconverted to DENV-1, but only subject CD1_2 was viremic, with a peak viral titer of 10 7 genome copies/mL (Table 4) .
DENV-3 Challenge
Of the 5 TDV recipients challenged with DENV-3, only subject TD3_3 was viremic with DENV-3 after the previous vaccination with TDV (data not shown). She was also viremic with DENV-1 and -2. The 3 TDV recipients who developed dengue-like illness on challenge, subjects TD3_1, TD3_2, and TD3_4, had reciprocal DENV-3 NAb titers of <10, 19, and 16, respectively, at the time of challenge. All 3 developed viremia detected by both delayed plaque assay and RT-PCR (Table 4 ). The magnitude of viremia was 5-7 log 10 genome copies/mL. Viremia was also detected in the 2 control subjects, at levels of 6-8 log 10 genome copies/mL. The duration of viremia was longer in the control subjects. Subjects TD3_3 and TD3_5 remained well after challenge; their prechallenge reciprocal titers were 57 and 116, respectively. Notably, subject TD3_3 did not have viremia detected by delayed plaque assay, but viremia was detected by RT-PCR, at a level of 4 log 10 genome copies/ mL. The 3 symptomatic vaccinees and the asymptomatic subject TD3_3 who were viremic all developed a marked rise in DENV-3 PRNT 50 titers after challenge, suggesting a secondary antibody response to viral replication. Subject TD3_5, who had the highest prechallenge titer, did not show any increase in NAb titer after challenge.
DENV-3 Revaccination
Subjects TV3_1 and TV3_2 did not seroconvert to DENV-3 1 month after TDV vaccination, but subject TV3_2 did so by the time of challenge. Neither developed viremia from DENV-3 revaccination. Subject TV3_1 had no DENV-3 NAb at the time of revaccination. He showed a pattern suggesting original antigenic sin, with seroconversions to DENV-2, -3, and -4, but had a much greater rise in DENV-2 antibody level. Subject TV3_2 had DENV-3 antibody detected at the time of challenge, and she did not show any rise in her antibodies after revaccination (Table 4) .
DISCUSSION
In monkeys given TDV, 1 or more DENV serotype(s) may dominate the antibody response, resulting in incomplete protection against the less dominant serotypes when the animals were subsequently challenged [13, 29, 30] . Similar NAb imbalance has been seen with all TDVs tested in humans to date [15, 16, [31] [32] [33] [34] . Strategies to mitigate such imbalance in the NAb response have included increasing the attenuation or lowering the dose(s) of the dominant serotype(s) and administering multiple doses of TDV, with various degrees of success. While it is generally accepted that the simultaneous induction of NAb to all 4 serotypes in each individual will likely predict protection against all 4 serotypes, this tetravalent seroconversion has been difficult to achieve. If it is assumed that seroconversion to each serotype is independent of seroconversion to the other serotypes, even a 90% rate for each individual serotype will lead to only a 66% tetravalent NAb response rate. In fact, the observed tetravalent seroconversion rates and titers may be due in part to cross-reactive NAb responses and therefore may overestimate long-term vaccine efficacy. This study is the first experimental DENV challenge of TDV recipients and was designed to explore the relationship between NAb from TDV vaccination and protection against disease. The subjects, who were living in an area where DENV is not endemic, were not exposed to wild-type DENV after their last TDV vaccination 8-42 months ago, and therefore their antibodies at the time of challenge were solely the result of their previous TDV vaccinations. Previous vaccination with TDV was associated with protection against DENV-1 challenge. Such protection may last 42 months after vaccination, as with subjects TD1_1 and TD1_3-5. The protection against DENV-1 appears to be mediated by sterile immunity, with no observed increase in NAb level from the challenge. Subject TD1_4 had a single episode of viremia, on day 7, detected by delayed plaque assay but not by RT-PCR. This may be due to the better sensitivity for DENV-1 exhibited by delayed plaque assay, compared with RT-PCR (10 vs 500 PFU/mL) [26] . In contrast, the protection against DENV-3 was variable. Three of the 5 TDV recipients developed clinical disease despite developing DENV-3 NAb from 2 doses of TDV. Of the 5 TDV recipients challenged with DENV-1, 4 were viremic with DENV-1 from their original vaccination with TDV. Of the 5 TDV recipients Data in parentheses indicate the day after inoculation on which the peak or nadir of the laboratory value was recorded.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; Hct, hematocrit; INR, international normalized ratio. a A neutrophil count of <1000 neutrophils/µL was considered to be abnormal.
b A platelet count of <100 000 platelets/µL was considered to be abnormal. challenged with DENV-3, only subject TD3_3 was viremic with the DENV-3 vaccine strain from her original TDV vaccination (data not shown). Interestingly, subject TD3_3 again developed DENV-3 viremia from challenge but had no associated dengue symptoms. Her serum had no culturable DENV-3, suggesting antibody neutralization of virus. The clinical courses of the DENV-3 breakthrough infections were consistent with dengue fever and not DHF. All 3 breakthrough infections, which occurred in subjects TD3_1, TD3_2, and TD3_4, had detectable viremia by both culture and RT-PCR, suggesting circulating infectious virus. The peak viremia titers in these 3 subjects were not enhanced and were comparable to titers in DENV-naive controls. Notably, the 2 TDV recipients protected against DENV-3, subjects TD3_3 and TD3_5, did not have viremia detected by culture, but subject TD3_3 had a peak viremia of 4 log 10 genome copies/mL detected by RT-PCR. Interestingly, these 2 protected subjects had the highest prechallenge DENV-3 NAb titers, at 1:57 (for subject TD3_3) and 1:116 (for subject TD3_5). The prechallenge NAb titer of 1:57 for subject TD3_3 was apparently not enough to prevent detection of viremia by RT-PCR but was enough to prevent detection of culturable virus from serum. Thus, high, long-lasting (≥ 9 months) postvaccination titers of NAb from TDV may be more predictive of protection. In TDV trials, the Nab titer measured 9 months or later after vaccination may be a better endpoint. This may be difficult in DENV-endemic areas where there is circulating virus and continuous exposure. Our study monitored for DHF, by vital signs, laboratory parameters, tourniquet tests, radiography, and abdominal ultrasonography. We previously showed that abdominal ultrasonography detected subclinical pericardial, perihepatic, and perisplenic effusions associated with DENV challenge [35] . Findings of abdominal ultrasonography in this study were unremarkable.
The challenge with DENV-3 was associated with marked elevations of AST and ALT levels in 2 TDV recipients, subjects TD3_1 and TD3_2, and in 1 control, subject CD3_1. Wild-type DENV infection is known to be associated with acute hepatitis, occasionally with markedly elevated results of liver functions tests, both in dengue fever and DHF [36, 37] . Four of 5 TDV recipients developed elevated AST and ALT levels. In subjects TD3_1 and TD3_2, the peak ALT levels were 20-fold and 10-fold, respectively, above the normal upper limit, and the onset of the elevation corresponded to the onset of dengue symptoms. The elevated AST and ALT levels were short-lived and resolved by the end of the study. Importantly, in our subjects with elevated AST and ALT levels, there were neither prolonged PTs nor bleeding, the complications associated with wild-type DENV infection with hepatitis [38, 39] . Elevated AST and ALT levels were also seen in control subject CD1_1 but not to the degree seen in subjects TD3_1 and TD3_2. Even without evidence of plasma leakage in subjects TD3_1 and TD3_2, the degree of elevation in results of liver function tests was in the range indicative of severe disease, according to the 2009 World Health Organization criteria [40] . During efficacy trials of TDV in DENV-endemic areas, there should be close monitoring to evaluate any increased incidence of acute liver disease in the vaccinated population, compared with that in controls.
There are obvious limitations to this study, given its small size. The subjects were selected from a limited pool of TDV recipients who received different formulations and schedules of TDV. The small size of the study precluded any meaningful assessment of the risk of DHF, as well as any demonstration of the level of NAb as a correlate of protection. The dose used for DENV-1 challenge was nearly 2 logs lower than the dose for DENV-3 challenge, making direct comparison of serotypes difficult. The lower DENV-1 challenge dose (10 3 PFU, compared with 10 5 PFU for DENV-3) may explain the delayed onset of clinical symptoms, on days 19 and 21, in the 2 DENV-1 control subjects and perhaps also the absence of DENV-1 viremia in subject CD1_1. Another possible limitation is the subcutaneous delivery of virus by needle injection, which may not completely replicate infection by mosquitoes. Our results suggest that TDV can induce long-term protection and that long-lasting, higher, serotype-specific NAb titers from TDV vaccination are more likely to predict vaccine-induced protective immunity. Durbin et al showed that when subjects previously vaccinated with DENV-1, -2, or -4 monovalent vaccines were challenged with fully attenuated heterotypic DENV-1 or -2 vaccines, no significant clinical or laboratory adverse events occurred [41] . This was not the case with our near-wild-type DENV-3 challenge, in which we observed that TDV failed to protect and that the challenge was associated with unexpected elevation of transaminase levels, suggesting liver injury. Given that a significant percentage of TDV recipients will not have protective tetravalent NAb responses, our study supports the wellrecognized need in field efficacy trials to include an extended safety follow-up period to monitor rates of complications from wildtype DENV infections in both the vaccinated and control groups.
The usefulness of experimental DENV challenge studies should be further evaluated. These studies will likely be limited in sample size but may be useful in selecting vaccine candidates for field trials. Alternatively, experimental challenge studies may serve as adjuncts to field efficacy trials to evaluate protection against noncirculating dengue serotypes.
Notes
